ALLMedicine™ Breast Biopsy Center

Jan 25th, 2023 - Guidelines recommend shared decision making (SDM) for mammography screening for women ≥ 75 and not screening women with < 10-year life expectancy. High-quality SDM requires consideration of women's breast cancer (BC) risk, life expectancy, and val...

Jan 24th, 2023 - Breast density is an independent risk factor for breast cancer. Despite the proliferation of mandated written notifications about breast density following mammography, there is little understanding of how women perceive the relative breast cancer ...

Jan 21st, 2023 - Breast Screen Australia and Breast Screen Aotearoa guidelines recommend breast biopsy marker (BBM) use in indicated patients. This study aims to evaluate whether BBM cost and availability impacts BBM utilisation. An online survey was disseminated ...

Jan 19th, 2023 - Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A ...

Jan 5th, 2023 - PRIMARY OBJECTIVE: I. Pre- versus (vs) post-intervention change in postpartum-related breast cancer (PRBC) score. SECONDARY OBJECTIVE: I. Pre- vs. post-intervention change in postpartum involution (PPI) signature score. EXPLORATORY OBJECTIVES: I. ...

Nov 28th, 2022 - Given that 20% to 40% of women who have percutaneous breast biopsy subsequently undergo breast surgery, knowledge of imaging women with a history of benign (including high-risk) disease or breast cancer is important. For women who had surgery for ...

Jan 19th, 2023 - Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A ...

Jan 5th, 2023 - PRIMARY OBJECTIVE: I. Pre- versus (vs) post-intervention change in postpartum-related breast cancer (PRBC) score. SECONDARY OBJECTIVE: I. Pre- vs. post-intervention change in postpartum involution (PPI) signature score. EXPLORATORY OBJECTIVES: I. ...

Dec 27th, 2022 - Participants in this study will have Multispectral Optoacoustic Tomography/MSOT imaging of both breasts immediately before their ultrasound-guided breast biopsy procedure begins. After the MSO imaging is completed, participation in the study will ...

Dec 19th, 2022 - INTRODUCTION Breast cancer has the highest incidence among women worldwide. Of the three methods (physical examination, imaging, and biopsy) in the diagnosis of breast lesions and breast cancer, the biopsy is a frequently used standard. A breast b...

Dec 19th, 2022 - Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population a...

Nov 4th, 2022 - The annual price of newly launched cancer drugs has increased 53% over the last 5 years, according to a report by U.S. Rep. Katie Porter (D-Calif.). (Reuters) A survey of large employers found that cancer has become the top driver of employer heal...

Oct 26th, 2022 - Women who chose not to have surgery after a pathologic complete response (pCR) to neoadjuvant therapy for early HER2-positive or triple-negative breast cancer (TNBC) had no recurrences during the first 2 years of follow-up, a small prospective stu...

Aug 23rd, 2022 - Note that some links may require subscriptions. CDC data show U.S. life expectancy dropped by nearly 2 years on average from 2019 to 2020, driven in large part by the COVID-19 pandemic; New York experienced the largest drop (3 years). A new case o...

Feb 16th, 2022 - A number of clinical trials in breast cancer have opened in recent months. Maybe one of your patients could benefit from being enrolled. Menopausal women at moderate risk of developing breast cancer. A phase 2 study sponsored by the National Cance...

Feb 2nd, 2022 - Vijayakrishna Gadi, MD, PhD: We have a little more information on this patient. We find out from the breast biopsy that she’s got 1 of these HER2 [human epidermal growth factor receptor 2]–enriched phenotypes. She’s hormone receptor–negative for e...